Previous Article | Next Article ![]()
Journal of Clinical Microbiology, May 2004, p. 2085-2093, Vol. 42, No. 5
0095-1137/04/$08.00+0 DOI: 10.1128/JCM.42.5.2085-2093.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Department of Microbiology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal,1 Mycotic Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 303332
Received 11 November 2003/ Returned for modification 8 January 2004/ Accepted 26 January 2004
|
|
|---|
0.91 for all genes except MDR1 (0.74). In this case, reduced correlation was due to the inability of Northern hybridization to accurately quantify the high MDR1 expression in a susceptible dose-dependent isolate which was shown by RT-LightCycler PCR to overexpress MDR1 >200-fold relative to the other isolates tested. In four isolates, low levels of CDR2 mRNA were detected by RT-LightCycler PCR but were undetectable by Northern hybridization. mRNA quantification by RT-LightCycler PCR correlates with Northern hybridization and offers additional advantages, including increased sensitivity and speed of analysis, along with lower RNA concentration requirements and an increased dynamic range of signal detection. |
|
|---|
Molecular mechanisms of azole resistance in C. albicans have been identified and include increased expression of the drug target (lanosterol 14-
-demethylase) encoded by ERG11, genetic alteration of ERG11 causing reduced azole affinity, and reduced intracellular accumulation of drug due to increased efflux mediated by multidrug efflux pumps (reviewed in references 18 and 22). Genes encoding drug efflux pumps include CDR1 and CDR2 from the ATP-binding cassette gene family and MDR1 from the major facilitator gene family (18, 22).
Quantification of drug resistance gene expression in C. albicans isolates with reduced fluconazole susceptibility is a valuable tool for understanding the molecular mechanism(s) of fluconazole resistance and monitoring for the emergence of resistance. Traditionally, mRNA quantification by Northern hybridization has been the method of choice for analyzing gene expression in C. albicans (1, 5, 6, 11, 12, 17). However, this method is labor intensive, requires several steps and multiple days to complete, requires relatively large amounts of RNA, and can lack the sensitivity required to detect small changes in gene expression.
More recently, non-real-time reverse transcriptase PCR (RT-PCR) methods for analyzing gene expression have improved sensitivity and increased throughput but still pose limitations with regard to accurate quantification (3, 14, 21). These non-real-time PCR methods measure amplified product at the end of the PCR and are thus subject to the errors caused by the plateauing effect that occurs when reagents become limiting. Moreover, because PCR amplification is exponential in nature, small changes in the amplification efficiency of a given reaction can produce dramatic differences in the amount of final product (3, 21). Therefore, quantification of the final product is not solely dependent upon the initial quantity of target template. Traditional RT-PCR methods also require post-PCR manipulations which take time and increase the risk of laboratory contamination with amplified product.
A further improvement to RT-PCR was accomplished with the introduction of real-time fluorescence PCR technology, which couples PCR with on-line fluorescence detection of amplification products (7, 23). Cycle-by-cycle monitoring of amplification enables discernment of the log-linear phase of amplification for more accurate quantification and eliminates the need for post-PCR sample processing to visualize and analyze products. Quantitative real-time RT-PCR has been successfully used for the measurement of gene expression in a variety of fields, including microbiology (8, 15, 20). The speed of RT-PCR has been further increased by ultra-fast LightCycler PCR, which uses forced air to rapidly heat and cool the chamber along with glass capillaries, which increase sample surface area and serve as natural cuvettes for fluorescence analysis. These features reduce the time to complete 30 cycles of a typical three-step PCR program to 30 min.
The RT-LightCycler PCR method described here couples reverse transcription and real-time PCR to quantify C. albicans ACT1, CDR1, CDR2, ERG11, and MDR1 mRNA in the absence of azole exposure. We utilized fluorescent-labeled, sequence-specific hybridization probes to increase the sensitivity and specificity of detection and quantification of amplified products. This report describes the development and optimization of the method and a comparison of results to those obtained by traditional Northern hybridization.
|
|
|---|
Broth microdilution susceptibility testing method.
MICs of fluconazole, itraconazole, and voriconazole were determined by the NCCLS M27-A broth dilution method (13). Standard powders of fluconazole and voriconazole were received as gifts from Pfizer Pharmaceuticals Group (Groton, Conn.), and itraconazole drug powder was purchased from Research Diagnostics, Inc. (Flanders, N.J.). The final concentrations of the antifungal agents ranged from 0.125 to 64 µg of fluconazole/ml and 0.015 to 8 µg of itraconazole and voriconazole/ml. The MIC endpoints were read visually following 24 and 48 h of incubation and were defined as the lowest concentration that produced a prominent reduction in growth (
50%) compared with that of the drug-free growth control. For fluconazole and itraconazole, MIC interpretations were assigned according to the NCCLS criteria (13). No interpretive breakpoints have been established for voriconazole. NCCLS-recommended quality control strains (ATCC 6258 and ATCC 22019) were included in each experiment, and MICs were within the recommended range for each test. Fluconazole MIC determinations were repeated on three different days to determine stability of the susceptibility phenotype.
Sterol quantification method. Total cellular ergosterol was quantified as previously described (2). The sterol quantification method MIC of fluconazole was defined as the concentration of drug which caused an 80% reduction in the total cellular ergosterol content compared to that in the drug-free control. MICs which fell between two drug concentrations (i.e., less than 80% reduction at one concentration but more than 80% reduction at the next-higher concentration) were mathematically extrapolated based on the amount of reduction by the drug concentration which gave results closest to an 80% reduction end point. Interpretations of fluconazole MICs were assigned according to the NCCLS criteria (13).
Relative quantification of gene expression by LightCycler RT-PCR. (i) RNA extraction. For each isolate, an overnight culture grown in 10 ml of SAB broth (Difco) was diluted 1:100 in fresh SAB broth and incubated with shaking at 35°C until cells reached the mid-logarithmic phase of growth (optical density at 600 nm = 0.8 to 1.0). Cells were harvested by centrifugation and washed once with sterile distilled water. Cell lysis was performed by resuspending cells in sterile distilled water plus lysis binding solution (Bio 101 Systems, Vista, Calif.), transferring into lysis matrix C tubes (Qbiogene, Carlsbad, Calif.), and vortexing twice for 45 s at speed level 6 in the FastPrep high-speed vortexer (Qbiogene). Total RNA was extracted using an RNAqueous-4PCR kit (Ambion, Austin, Tex.) following the manufacturer's directions. To remove genomic DNA contamination, RNA samples were treated with 2 U of DNase I (Ambion) per 50 µl of RNA at 37°C for 1 h.
(ii) Synthesis of cDNA. Reverse transcription was performed in a total volume of 20 µl with a 1st Strand cDNA synthesis kit for RT-PCR (Roche Molecular Biochemicals, Indianapolis, Ind.) using 1 µl of RNA, avian myeloblastosis virus RT, and random primer p(dN)6, as recommended by the manufacturer. The cDNA was purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.) and quantified by spectrophotometric measurement of the A260 and A280 and standard calculations.
(iii) Quantitative real-time PCR with LightCycler. Oligonucleotide primers and hybridization probes were designed using LightCycler probe design software (Roche) and are listed in Table 1. In order to optimize the real-time PCR conditions, the optimal MgCl2 concentration and annealing temperature were determined using FastStart DNA Master SYBR Green I (Roche) for LightCycler PCR. In this format, the double-stranded specific, DNA-binding dye, SYBR Green I, was used to detect amplicons instead of fluorescent-labeled hybridization probes. To verify the specificity of the PCR amplification products, LightCycler melting curve analysis was performed using the following thermal cycling profile: 95°C for 0 s, 65°C for 15s, and ramping to 95°C with stepwise signal acquisition. To further verify the specificity of the LightCycler PCR, 5 µl of amplification product was subjected to gel electrophoresis using a 1.2% agarose-TBE (89 mM Tris-borate, 2 mM EDTA; pH 8.3) gel with 1x TBE running buffer. DNA bands were visualized with UV light following ethidium bromide staining.
|
View this table: [in a new window] |
TABLE 1. Primers and probes used for RT-LightCycler PCR and Northern hybridization probe synthesis
|
A standard curve was prepared for each gene (ACT1, CDR1, CDR2, ERG11, and MDR1) by purification and 10-fold serial dilutions of the respective amplicons (generated as described above) (4). For quantification, LightCycler PCR was performed using the FastStart DNA master hybridization probe PCR mix (Roche). The reaction mixture consisted of 2.4 µl of 25 mM MgCl2, a 0.4 µM concentration of each PCR primer, 0.2 µM concentration of each hybridization probe, 2 µl of LightCycler DNA FastStart hybridization mix (Roche), and PCR-grade water up to a final volume of 18 µl. For all samples, a master mix was prepared and 18 µl was transferred into each glass capillary. Two microliters of cDNA from the reverse transcription step (test samples) or PCR amplicons from each dilution (standard curve) were then pipetted into all but one of the LightCycler capillaries. PCR-grade water was added to the latter in place of template to serve as a negative control. Each RNA preparation was tested for genomic DNA contamination in a LightCycler PCR by replacing cDNA template with 2 µl of purified RNA. After 10 min of denaturation at 95°C, 40 to 50 PCR cycles were performed. Cycling conditions were 95°C for 10 s, 62°C for 15 s, and 72°C for 10 s. The concentration of each gene was calculated by reference to the respective standard curve with the aid of the LightCycler software. Relative gene expression was expressed as a ratio of target gene (ERG11, CDR1, CDR2, and MDR1) concentration to housekeeping gene (ACT1) concentration, and values reported represent the mean gene expression from three separate LightCycler PCR experiments using the same RNA preparation ± the standard deviation (SD).
Northern hybridization. (i) Gel electrophoresis and transfer. Total RNA from each C. albicans strain was obtained as described above. For Northern hybridization, equal amounts (approximately 5 µg) of RNA from each strain were denatured by adding 3 volumes of formaldehyde loading dye (RNAqueous kit; Ambion) and heating at 65°C for 15 min. RNA samples were then subjected to electrophoresis in a denaturing gel containing 1.2% agarose, 2% formaldehyde, and 1x morpholinepropanesulfonic acid (MOPS) buffer (40 mM MOPS, 10 mM sodium acetate, 1 mM EDTA; pH 7.0). Samples were loaded and electrophoresed in 1x MOPS buffer at 30 V until the bromophenol blue had migrated two-thirds of the length of the gel. Northern transfer was performed by capillary transfer overnight onto positively charged, nylon membrane (Roche) with 20x SSC (3 M NaCl, 0.3 M sodium citrate) as transfer buffer. RNA was fixed onto the membrane by UV cross-linking following the manufacturer's recommendations (SpectroLinker, Westbury, N.Y.).
(ii) Probe synthesis and hybridization. Digoxigenin (DIG)-labeled DNA probes specific for ERG11, CDR1, CDR2, MDR1, and ACT1 were synthesized by PCR using the PCR Dig probe synthesis kit (Roche), genomic DNA from the fluconazole-susceptible C. albicans isolate ATCC 32354 as template, and gene-specific oligonucleotide primers (sequences shown in Table 1). Cycling conditions for ERG11, MDR1, and ACT1 were one cycle at 95°C for 5 min, followed by 30 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s, followed by one cycle at 72°C for 7 min. Cycling conditions for CDR1 and CDR2 were the same as above except the annealing temperature was reduced to 52°C. The samples were held at 4°C in the thermal cycler until retrieved. Positive control amplification reactions were included for each gene, using the same DNA template, primers, and cycling conditions but with unlabeled nucleotides. Efficiency of DIG labeling was determined by electrophoresis of 5 µl of DIG-labeled and 5 µl of unlabeled reaction products through a 1.2% agarose-TBE gel with 1x TBE running buffer. A shift in the expected molecular weight between labeled and unlabeled product indicated efficient incorporation of DIG-labeled nucleotides. Separate but identical blots were probed simultaneously with 3 µl of ACT1 probe and 4 µl of a target gene probe (CDR1, CDR2, ERG11, or MDR1) per ml of DIG Easy Hyb solution (Roche) at 42°C, overnight. Posthybridization washes were carried out using the DIG Wash and Block buffer system (Roche) following the manufacturer's directions.
(iii) Detection and quantification of target gene expression. DIG-labeled probe-RNA hybrids were detected using CDP-Star (Roche) following the manufacturer's directions. Chemiluminescent signals were quantified using the LumiImager F1 workstation and LumiAnalyst software (Roche). For each isolate, target gene expression was calculated relative to ACT1 expression to adjust for differences in RNA loading. Two independent Northern hybridization experiments were performed for each gene-isolate combination (using the same RNA preparation), and the average of the results is reported.
Statistical analysis. Student's t test (two-tailed; two-sample test with unequal variance) was used to determine significant differences in gene expression, as determined by LightCycler RT-PCR, for isolates with different fluconazole susceptibility phenotypes. Pearson's product moment correlation coefficient r was used to determine correlations between Northern hybridization and RT-LightCycler PCR results for each target gene.
|
|
|---|
|
View this table: [in a new window] |
TABLE 2. In vitro susceptibilities of the 10 C. albicans isolates used in this study
|
![]() View larger version (27K): [in a new window] |
FIG. 1. Specificity of LightCycler PCR for amplification of C. albicans genes ERG11 (A), CDR1 (B), CDR2 (C), MDR1 (D), and ACT1 (E) as determined by melting curve analysis. Melting peaks were determined by plotting the continuous negative derivative of fluorescence emitted by each sample as PCR products were slowly melted. The no-template control sample for each reaction does not show fluorescence, confirming the absence of primer dimers.
|
![]() View larger version (41K): [in a new window] |
FIG. 2. Agarose gel electrophoresis of LightCycler PCR products. A single band of the expected molecular weight confirms the specificity of the LightCycler PCR. The absence of a band in the no-template samples indicates the absence of primer dimers. Lanes: M, molecular weight marker IX (Roche); 1, ACT1 amplicon; 2, ACTI no-template control (NTC); 3, MDR1 amplicon; 4, MDR1 NTC; 5, ERG11 amplicon; 6, ERG11 NTC; 7, CDR1 amplicon; 8, CDR1 NTC; 9, CDR2 amplicon; 10, CDR2 NTC.
|
2.0. After optimizing magnesium concentration and annealing temperature and, in some cases, redesigning LightCycler PCR primers, E values for both the drug resistance genes and ACT1 ranged between 1.768 and 1.885. Figure 3 shows representative LightCycler PCR amplification curves and the respective standard curves for ACT1, CDR1, CDR2, ERG11, and MDR1 using four 10-fold serial dilutions of homologous, in vitro-synthesized DNA template.
![]() View larger version (40K): [in a new window] |
FIG.3. LightCycler PCR amplification curves and their respective standard curves from four 10-fold serial dilutions of in vitro-synthesized, C. albicans genes ERG11 (A), CDR1 (B), CDR2 (C), MDR1 (D), and ACT1 (E). For amplification curves, the amount of fluorescence emitted from each sample was measured at the end of each PCR cycle and plotted against the respective PCR cycle number. For the standard curves, log concentration of each standard (as entered by user) was plotted against the cycle number where fluorescence emerged from background during amplification. The E (efficiency) value is shown for each LightCycler standard curve.
|
Quantification of ACT1, CDR1, CDR2, ERG11, and MDR1 expression in the absence of azole exposure among C. albicans isolates with varying susceptibilities to fluconazole. (i) LightCycler real-time PCR.
Following reverse transcription of mRNA, cDNA was amplified and quantified by LightCycler real-time PCR to determine the expression of ACT1, CDR1, CDR2, ERG11, and MDR1. For each C. albicans isolate, expression of CDR1, CDR2, ERG11, and MDR1 was normalized with ACT1 expression (from the respective isolate) by representing the results as a ratio of resistance gene expression to housekeeping gene expression (ACT1). Results for all 10 isolates are shown in Table 3 and represent the mean expression ± SD for three independent LightCycler PCR runs. ERG11 expression was significantly higher in the fluconazole-resistant isolates compared to the SDD and susceptible isolates, as well as in the SDD isolates compared to the susceptible isolates (P
0.05). CDR1 and CDR2 overexpression was observed in the fluconazole-resistant isolates compared to the susceptible isolates (P
0.08). MDR1 expression was less consistent in that only a single fluconazole-SDD isolate expressed high levels while the other nine isolates (including susceptible, SDD, and resistant) expressed very little or no MDR1.
|
View this table: [in a new window] |
TABLE 3. LightCycler quantification of C. albicans ERG11, CDR1, CDR2, and MDR1 mRNA
|
(ii) Northern hybridization. Northern hybridization is currently the most commonly used method for quantifying gene expression in Candida species isolates. Therefore, we compared quantification by this novel RT-LightCycler PCR method with that of Northern hybridization using sequence-specific probes. Figure 4 shows the Northern hybridization results of ACT1, CDR1, CDR2, ERG11, and MDR1 expression for all 10 C. albicans isolates grown in the absence of azole antifungals. Densitometry was used to quantify the Northern blots, and gene expression, relative to ACT1, was determined for each isolate (Fig. 4). The Northern hybridization images in Fig. 4 are from representative experiments, while the densitometry values shown are the average of two independent experiments. Northern hybridization analysis failed to detect low levels of CDR2 expression in one of the SDD isolates (isolate 7) and in all three of the susceptible isolates (isolates 8 to 10). Six of the 10 isolates, including one fluconazole-resistant, two SDD, and all three susceptible isolates (isolates 1, 4, 6, and 8 to 10), lacked MDR1 expression by Northern hybridization (Fig. 4).
![]() View larger version (114K): [in a new window] |
FIG. 4. Quantification of C. albicans CDR1, CDR2, ERG11, and MDR1 mRNA by Northern hybridization. Quantification of target gene expression was accomplished using densitometry of chemiluminescent signals. Expression of drug resistance genes was normalized to that of ACT1 expression in the same isolate. Densitometry values shown below each image are the average of two independent experiments.
|
|
|
|---|
Northern hybridization is a well-established method for RNA analysis and has been useful for characterizing drug resistance gene expression in clinical isolates of C. albicans (1, 5, 6, 11, 12, 17). However, in the era of PCR and specifically with the advent of RT-PCR, quantification of mRNA using these modern approaches offers significant advantages over Northern hybridization. These include increased sensitivity for detection of low-abundance mRNAs, increased dynamic range of detection for more accurate quantification, a "micro" format to support high-throughput screening applications, and the ability to convert unstable RNA template into cDNA, which is less susceptible to degradation. The LightCycler system, which couples high-speed PCR with on-line fluorescent detection of amplification products, adds additional advantages to RT-PCR, including quantification during the log-linear phase of amplification, increased speed of analysis, and no need for post-PCR sample processing.
To date, a few reports have described the application of LightCycler PCR to the detection, identification, or quantification of fungal cells (9, 10, 15, 19). However, none have applied this technology to quantify the expression of the known drug resistance genes in C. albicans. Loeffler et al. (10) described a quantitative LightCycler PCR assay to detect C. albicans and Aspergillus fumigatus DNA in human blood specimens with high sensitivity and specificity. Although these authors' previously published PCR-enzyme-linked immunosorbent assay was equally sensitive, the LightCycler assay decreased the time to results by 2 h (10). Another report described the use of LightCycler PCR to detect point mutations in C. albicans and Candida tropicalis ERG11 from isolates with decreased fluconazole susceptibility (9). This approach took advantage of the LightCycler melting curve function to detect differences in Tm among clinical isolates with different ERG11 genotypes. When compared to conventional cycle sequencing, the LightCycler method performed equally well in the case of C. albicans. For C. tropicalis, the LightCycler method detected a heterozygous genotype in five isolates that was not detected in the same five isolates by conventional cycle sequencing. Excellent sensitivity and specificity of the LightCycler assay were demonstrated by these investigators and, coupled with the ability to analyze 32 samples per 45-min run, the potential for rapid screening was noted (9). Selvarangan et al. (19) described a different application of the LightCycler melting curve function to differentiate between the germ-tube-positive yeasts C. albicans and Candida dubliniensis. This method utilized a single fluorescent-labeled nucleic acid probe which bound equally well to LightCycler PCR products from both species but disassociated from each at a characteristic temperature. Differentiation between the two species was accomplished in 2 h or less by detection of peak fluorescence at the species-specific Tm (19). The fourth report described the use of LightCycler real-time RT-PCR to quantify C. albicans actin mRNA as a means of assessing viability in a model of cutaneous candidiasis (15). Results demonstrated the sensitivity of the method in detecting 1 fg of the plasmid DNA containing a 192-bp fragment of the ACT1 exon (pACT) in real time, with a reproducibility of 100% among five replicates (15). Each of these assays illustrates a unique application of the LightCycler technology, while all share the common features of excellent sensitivity, specificity, and speed of analysis. Furthermore, these studies demonstrate the flexibility of the LightCycler system and its usefulness in both the research laboratory as well as the routine clinical laboratory.
The novel RT-LightCycler PCR assay described here for the relative quantification of mRNA is yet another application of real-time PCR. To increase sensitivity and specificity of the assay, we added sequence-specific hybridization probes to detect C. albicans ACT1, CDR1, CDR2, and MDR1 LightCycler PCR products. This detection format uses two oligonucleotide probes, labeled with different fluorescent dyes, which bind very closely to each other on the target sequence. It is only when the dyes are in close proximity to each other, as when bound to the target sequence, that a fluorescent light is emitted. Therefore, in the absence of target sequence, no fluorescence is detected. This approach, unlike the SYBR Green I dye, which binds nonspecifically to all double-stranded DNA, eliminates the contribution of nonspecific amplification products, such as primer dimers, to the quantification of the target sequence.
Quantification of mRNA from the clinical C. albicans isolates was achieved by extrapolation from standard curves generated from known concentrations of standard DNA templates. Therefore, careful consideration was given to designing a standard curve to ensure that amplification efficiencies of target sequences were the same for both the test samples and the standards. For this method, we prepared external standards of in vitro-synthesized ACT1, CDR1, CDR2, ERG11, and MDR1 sequences and included the appropriate standard curves in every LightCycler PCR experiment. Therefore, the concentration of target in the test samples was calculated based on its specific standard curve that was generated during the same LightCycler PCR run. Although this conservative approach added five additional reaction tubes per target gene per LightCycler PCR and thereby reduced the number of test samples that could be analyzed in a given run, it eliminated any concern of variation that may occur between individual LightCycler PCR runs. Upon analysis of our results from multiple LightCycler PCR runs, we found run-to-run variation to be minor and the practice of using a previously generated and stored standard curve to quantify target sequence concentration in test samples acceptable.
In conclusion, the RT-LightCycler PCR method for C. albicans mRNA quantification correlated well with traditional Northern hybridization while offering several advantages, including increased sensitivity and specificity, accurate quantification of very low and very high mRNA quantities, increased throughput and speed of analysis, and a closed-tube system that does not require post-PCR sample analysis. The use of this novel RT-LightCycler PCR assay to rapidly screen clinical C. albicans isolates and quantify the expression of known drug resistance genes could be a valuable complement to in vitro antifungal susceptibility testing for detecting and monitoring the emergence of azole antifungal drug resistance. Adaptation of this method to screen non-C. albicans species of Candida is under way.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»